Literature DB >> 15986014

Vascular access complications in daily dialysis: a systematic review of the literature.

S Shurraw1, D Zimmerman.   

Abstract

Patients treated for end stage renal disease (ESRD) have a shorter life expectancy and a poorer quality of life than the general population. In an attempt to improve outcomes for this patient population, a few novel therapeutic approaches have been undertaken. With hemodialysis, an increase in dialysis frequency and/or time has been associated with improvements in anemia, left ventricular hypertrophy, hypertension, hyperphosphatemia, nutrition and quality of life. Yet, access to these promising hemodialysis modalities has remained limited. The reasons for this are numerous, but one concern is the potential for more frequent vascular access complications with the increased frequency of cannulation for an arteriovenous fistula/graft and connection for a central venous catheter. In this systematic review of the literature, we identified all published studies that included 10 or more patients on daily hemodialysis and reported quantitative data pertaining to vascular access complications. Twelve studies met our inclusion criteria. The overall complication rates associated with vascular access do not appear to be increased and are perhaps even decreased with daily compared to conventional thrice-weekly hemodialysis. Arteriovenous fistulas are the vascular access of choice for daily hemodialysis; however, a non-statistically significant increased complication rate for these accesses was reported in 2 North American studies. The reasons for this are unclear and require further research.

Entities:  

Mesh:

Year:  2005        PMID: 15986014

Source DB:  PubMed          Journal:  Minerva Urol Nefrol        ISSN: 0393-2249            Impact factor:   3.720


  8 in total

1.  Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients.

Authors:  Eric D Weinhandl; Jiannong Liu; David T Gilbertson; Thomas J Arneson; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2012-02-23       Impact factor: 10.121

2.  Risk of vascular access complications with frequent hemodialysis.

Authors:  Rita S Suri; Brett Larive; Susan Sherer; Paul Eggers; Jennifer Gassman; Sam H James; Robert M Lindsay; Robert S Lockridge; Daniel B Ornt; Michael V Rocco; George O Ting; Alan S Kliger
Journal:  J Am Soc Nephrol       Date:  2013-02-07       Impact factor: 10.121

3.  Buttonhole versus Stepladder Cannulation for Home Hemodialysis: A Multicenter, Randomized, Pilot Trial.

Authors:  Shih-Han S Huang; Jennifer MacRae; Dana Ross; Rameez Imtiaz; Brittany Hollingsworth; Gihad E Nesrallah; Michael A Copland; Philip A McFarlane; Christopher T Chan; Deborah Zimmerman
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-18       Impact factor: 8.237

4.  Forensic issues in cases of fatal hemorrhage from arteriovenous dialysis access sites.

Authors:  Roger W Byard; Ross A James
Journal:  Forensic Sci Med Pathol       Date:  2007-07-10       Impact factor: 2.007

5.  Paradoxical embolism after declotting of hemodialysis fistulae/grafts in patients with patent foramen ovale.

Authors:  Steven Wu; Iftikhar Ahmad; Sohail Qayyum; Stephan Wicky; Sanjeeva P Kalva
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-05       Impact factor: 8.237

6.  Need for quality improvement in renal systematic reviews.

Authors:  Marko Mrkobrada; Heather Thiessen-Philbrook; R Brian Haynes; Arthur V Iansavichus; Faisal Rehman; Amit X Garg
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-09       Impact factor: 8.237

7.  An economic assessment model for in-center, conventional home, and more frequent home hemodialysis.

Authors:  Paul Komenda; Meghan B Gavaghan; Susan S Garfield; Amy W Poret; Manish M Sood
Journal:  Kidney Int       Date:  2011-10-12       Impact factor: 10.612

8.  The association of erythropoietin-stimulating agents and increased risk for AV-fistula dysfunction in hemodialysis patients. A retrospective analysis.

Authors:  Anna Wärme; Henrik Hadimeri; Salmir Nasic; Bernd Stegmayr
Journal:  BMC Nephrol       Date:  2021-01-18       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.